Drug design tools -in silico, in vitro and in vivo ADME/PK prediction and interpretation: Is PK in monkey an essential part of a good human PK prediction?

Current Topics in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 351-357

  Hosea, Natilie A ^a  

^a PFIZER INC   (United States)

Author keywords

Clearance; In silico; In vitro; PBPK; Pharmacokinetics; Prediction; Scaling

Indexed keywords

ARTICLE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; HAPLORHINI; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PREDICTION; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; HAPLORHINI; HUMANS; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 79551675770     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794480954     Document Type: Article

References (64)

1. Lave, T.; Chapman, K.; Goldsmith, P.; Rowland, M. Human clearance prediction: shifting the paradigm. Expert Opin. Drug Metab. Toxicol., 2009, 5, (9), 1039-1048.
2. Mahmood, I.; Balian, J.D. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica, 1996, 26(9), 887-895.
3. Lave, T.; Coassolo, P.; Reigner, B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin. Pharmacokinet., 1999, 36(3), 211-231.
4. Feng, M.R.; Lou, X.; Brown, R.R.; Hutchaleelaha, A. Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm. Res., 2000, 17, (4), 410-418.
5. Mahmood, I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J. Clin. Pharmacol., 2000, 40(12 Pt 2), 1439-1446.
6. Nagilla, R.; Ward, K.W. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J. Pharm. Sci., 2004, 93(10), 2522-2534.
7. Poggesi, I. Predicting human pharmacokinetics from preclinical data. Curr. Opin. Drug Discov. Devel., 2004, 7, (1), 100-111.
8. Ward, K.W.; Smith, B.R. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos., 2004, 32(6), 603-611.
9. Ward, K.W.; Smith, B.R. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab. Dispos., 2004, 32(6), 612-619.
10. Ito, K.; Houston, J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res., 2005, 22(1), 103-112.
11. Jolivette, L.J.; Ward, K.W. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J. Pharm. Sci., 2005, 94(7), 1467-1483.
12. Tang, H.; Mayersohn, M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos., 2005, 33(9), 1297-1303.
13. Tang, H.; Hussain, A.; Leal, M.; Mayersohn, M.; Fluhler, E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab. Dispos., 2007, 35(10), 1886-1893.
14. Hosea, N.A.; Collard, W.T.; Cole, S.; Maurer, T.S.; Fang, R.X.; Jones, H.; Kakar, S.M.; Nakai, Y.; Smith, B.J.; Webster, R.; Beaumont, K., Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol., 2009, 49(5), 513-533.
15. Goteti, K.; Garner, C.E.; Mahmood, I. Prediction of human drug clearance from two species: a comparison of several allometric methods. J. Pharm. Sci., 2010, 99(3), 1601-1613.
16. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32(11), 1201-1208.
17. Wrighton, S.A.; Stevens, J.C., The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 1992, 22(1), 1-21.
18. Nelson, D.R.; Kamataki, T.; Waxman, D.J.; Guengerich, F.P.; Estabrook, R.W.; Feyereisen, R.; Gonzalez, F.J.; Coon, M.J.; Gunsalus, I.C.; Gotoh, O. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 1993, 12(1), 1-51.
19. Inoue, H.; Castagnoli, K.; Van Der Schyf, C.; Mabic, S.; Igarashi, K.; Castagnoli, N., Jr. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. J. Pharmacol. Exp. Ther., 1999, 291(2), 856-864.
20. Sugihara, K.; Katsuma, Y.; Kitamura, S.; Ohta, S.; Fujitani, M.; Shintani, H. Cynomolgus monkey liver aldehyde oxidase: extremely high oxidase activity and an attempt at purification. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 2000, 126(1), 53-60.
21. Martignoni, M.; Groothuis, G.; de Kanter, R.Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab. Dispos., 2006, 34(6), 1047-1054.
22. Martignoni, M.; Groothuis, G.M.; de Kanter, R.Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert. Opin. Drug Metab. Toxicol., 2006, 2(6), 875-894.
23. Lai, Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin. Drug Metab. Toxicol., 2009, 5(10), 1175-1187.
24. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283(1), 46-58.
25. Ripp, S.L.; Bushee, J.L.; Hagen, A.E.; Magee, T.V.; Obach, R.S.; Strelevitz, T.J.; Vaz, A.D. In Vitro/In Vivo Correlation for Aldehyde Oxidase-Mediated Metabolism of N-Heterocyclic Xenobiotics. 15th North American Regional ISSX Meeting, 2008, (#85).
26. Zientek, M.; Jiang, Y.; Youdim, K.; Obach, R.S. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab. Dispos., 2010, 38(8), 1322-1327.
27. Miners, J.O.; Mackenzie, P.I.; Knights, K.M. The prediction of drug-glucuronidation parameters in humans: UDPglucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab. Rev., 2010, 42(1), 189-201.
28. Dedrick, R.L. Animal scale-up. J. Pharmacokinet. Biopharm., 1973, 1(5), 435-461.
29. Boxenbaum, H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm., 1980, 8(2), 165-176.
30. Hu, T.-M.; Chiu, S.-J. Prediction of human drug clearance using a single-species, fixed-exponent allometric approach. J. Med. Sci., 2009, 29(6), 331-339.
31. Beedham, C.; Bruce, S.E.; Critchley, D.J.; al-Tayib, Y.; Rance, D.J. Species variation in hepatic aldehyde oxidase activity. Eur. J. Drug Metab. Pharmacokinet., 1987, 12(4), 307-310.
32. Itoh, K.; Maruyama, H.; Adachi, M.; Hoshino, K.; Watanabe, N.; Tanaka, Y. Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica, 2007, 37(7), 709-716.
33. Lombardo, F.; Obach, R.S.; Shalaeva, M.Y.; Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem., 2002, 45(13), 2867-2876.
34. Lombardo, F.; Obach, R.S.; Shalaeva, M.Y.; Gao, F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J. Med. Chem., 2004, 47(5), 1242-1250.
35. Lombardo, F.; Obach, R.S.; Dicapua, F.M.; Bakken, G.A.; Lu, J.; Potter, D.M.; Gao, F.; Miller, M.D.; Zhang, Y.A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J. Med. Chem., 2006, 49(7), 2262-2267.
36. Berellini, G.; Springer, C.; Waters, N.J.; Lombardo, F. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. J. Med. Chem., 2009, 52(14), 4488-4495.
37. Parrott, N.; Paquereau, N.; Coassolo, P.; Lave, T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci., 2005, 94(10), 2327-2343.
38. Jones, H.M.; Parrott, N.; Jorga, K.; Lave, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet., 2006, 45(5), 511-542.
39. De Buck, S.S.; Sinha, V.K.; Fenu, L.A; Nijsen, M.J.; Mackie, C.E.; Gilissen, R.A. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos., 2007, 35(10), 1766-1780.
40. Jones, H.M.; Gardner, I.B.; Collard, W.T.; Stanley, P.J.; Oxley, P.; Hosea, N.A.; Plowchalk, D.; Gernhardt, S.; Lin, J.; Dickins, M.; Rahavendran, R.; Jones, B.C.; Watson, K.J.; Pertinez, H.; Kumar, V.; Cole, S. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin. Pharmacokinet., 2010, in press.
41. Kwan, K.C. Oral bioavailability and first-pass effects. Drug Metab. Dispos., 1997, 25(12), 1329-1336.
42. Kolars, J.C.; Lown, K.S.; Schmiedlin-Ren, P.; Ghosh, M.; Fang, C.; Wrighton, S.A.; Merion, R.M.; Watkins, P.B. CYP3A gene expression in human gut epithelium. Pharmacogenetics, 1994, 4(5), 247-259.
43. Thummel, K.E.; O'Shea, D.; Paine, M.F.; Shen, D.D.; Kunze, K.L.; Perkins, J.D.; Wilkinson, G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 1996, 59(5), 491-502.
44. Paine, M.F.; Shen, D.D.; Kunze, K.L.; Perkins, J.D.; Marsh, C.L.; McVicar, J.P.; Barr, D.M.; Gillies, B.S.; Thummel, K.E.First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther., 1996, 60(1), 14-24.
45. Shen, D.D.; Kunze, K.L.; Thummel, K.E.Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev., 1997, 27(2-3), 99-127.
46. Paine, M.F.; Khalighi, M.; Fisher, J.M.; Shen, D.D.; Kunze, K.L.; Marsh, C.L.; Perkins, J.D.; Thummel, K.E.Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J. Pharmacol. Exp. Ther., 1997, 283(3), 1552-1562.
47. Fisher, M.B.; Labissiere, G.The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr. Drug Metab., 2007, 8(7), 694-699.
48. Kadono, K.; Akabane, T.; Tabata, K.; Gato, K.; Terashita, S.; Teramura, T. Quantitative prediction of intestinal metabolism in humans from simplified fg model and empirical scaling factor. Drug Metab. Dispos., 2010.
49. Benet, L.Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 2009, 6(6), 1631-1643.
50. Pang, K.S.; Maeng, H. J.; Fan, J. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm., 2009, 6(6), 1734-1755.
51. Chiou, W. L.; Barve, A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res., 1998, 15(11), 1792-1795.
52. Chiou, W. L.; Jeong, H.Y.; Chung, S. M.; Wu, T. C. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res., 2000, 17(2), 135-140.
53. Chiou, W. L.; Buehler, P.W. Comparison of oral absorption and bioavailablity of drugs between monkey and human. Pharm. Res., 2002, 19(6), 868-874.
54. Takahashi, M.; Washio, T.; Suzuki, N.; Igeta, K.; Fujii, Y.; Hayashi, M.; Shirasaka, Y.; Yamashita, S. Characterization of gastrointestinal drug absorption in cynomolgus monkeys. Mol. Pharm., 2008, 5(2), 340-348.
55. Akabane, T.; Tabata, K.; Kadono, K.; Sakuda, S.; Terashita, S.; Teramura, T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab. Dispos., 2010, 38(2), 308-316.
56. Parrott, N.; Lukacova, V.; Fraczkiewicz, G.; Bolger, M. B. Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. AAPS J., 2009, 11(1), 45-53.
57. Jones, H.M.; Gardner, I. B.; Watson, K.J. Modelling and PBPK simulation in drug discovery. AAPS J., 2009, 11(1), 155-166.
58. Heimbach, T.; Lakshminarayana, S. B.; Hu, W.; He, H. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J., 2009, 11(3), 602-614.
59. goram, B.; Woltosz, W. S.; Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev., 2001, 50 (Suppl 1), S41-67.
60. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm., 1999, 186(2), 119-125.
61. Obach, R.S. The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. Drug Discov. Devel., 2001, 4(1), 36-44.
62. Wagner, J. G. Dosage intervals based on mean residence times. J. Pharm. Sci., 1987, 76(1), 35-38.
63. Boxenbaum, H.; Battle, M. Effective half-life in clinical pharmacology. J. Clin. Pharmacol., 1995, 35(8), 763-766.
64. Gabrielsson, J.; Weiner, D. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. 3rd ed.; Apotekarsocieteten: [Stockholm], 2000; p. 924.